PlasmaSELECT™ 64

PlasmaSELECT™ 64 analyzes circulating tumor DNA for genetic alterations in cancer,eliminating the need for an invasive biopsy or tumor tissue. PlasmaSELECT™ 64 may also be used to evaluate subclonal mutations in tumor tissue, when available. PlasmaSELECT™ 64 evaluates a targeted panel of 64 well-characterized cancer genes. Cell-free DNA is extracted from plasma and prepared using proprietary methods that accommodate low abundance sample DNA. Samples are processed using a proprietary capture process and high coverage next-generation sequencing to allow tumor-specific (somatic) mutations and translocations to be identified with a high sensitivity and specificity. Analyses for sequence mutations, rearrangements or microsatellite instability (MSI) can be performed together or separately, depending on the specific alterations of interest.